Introduction Kidney Disease: Improving Glob al Outcomes (KDIGO) is a global nonprofit or ganization established in 2003 and governed by an inter national board consisting of representa tives from 24 countries and 5 continents. It is dedicated to coordinating and integrating inter national collaboration initiatives aiming at im proving the care and outcomes of kidney dis ease patients worldwide and establishing objec tives for research. Among its several initiatives, KDIGO is actively involved in sponsoring the so called Controversies Conferences, bringing to gether inter national experts in different fields of nephrology. The purpose of the Conferences is to establish a set of common inter national clinical guidelines, and subsequently, to introduce them into everyday clinical practice. Such coordination seems necessary, because a number of various inter national organizations and societies have been established recently, each publishing their own sets of rules and guidelines. Since develop ment of highquality guidelines requires a consid erable financial and scientific effort, the KDIGO initiative offers a unique opportunity to conserve major resources.
KDIGO devoted almost 4 years of thorough research to chronic kidney diseasemineral and bone disorder (CKDMBD). A 2005 conference entitled "Definition, Evaluation and Classifica tion of Renal Osteodystrophy" initiated the en tire process and led to the publication of a 2006 manifest, which stated the need for change in the definition of the disease as well as for the new guidelines. A task group, aided by experts from the KDIGO Evidence Review Team, spent 2 years reviewing inter national literature on the subject of kidney transplant bone disease. Finally, future research directions are presented.
definition The traditional term "renal osteo dystrophy", which has been used until recently, failed to encompass the entire spectrum of bone and mineral abnormalities, because the dramatic effect of mineral disorder on cardiovascular system in uremia had not been fully known at the time. As the clinical evidence grew, the need for change of the definition became more apparent, "bone and vascular disease" being one of the possible options. Eventually, the term CKDMBD was in troduced to describe a broader clinical syndrome that included mineral disturbance and abnormal meta bolism of boneregulating hormones, as well as various bone disorders and calcification of soft tissues (FIGURE) . All these types of patho logies are inter related and together account for unfavorable prognosis in CKD. Therefore, the term "renal os teodystrophy" as a part of the above mentioned syndrome is to be used only with respect to patho logical changes within the bone. The precise diag nosis and classification of these patho logies re quires bone bio psy and a thorough histomorpho metric examination.
diagnosis of CKd-Mbd: bio chemical abnormalities
Biochemical abnormalities play a central role in the diagnostic and therapeutic approach in CKDMBD. The earliest detectable changes affect the levels of boneregulating hormones. Increased PTH levels and decreased 25(OH)D 3 (calcidiol) and 1,25(OH) 2 D 3 levels are observed already in stage 3 of CKD, while calcium and phosphorus lev els are usually normal until more advanced stag es of the disease. Therefore, bio chemical para meters should be closely monitored already in stage 3 CKD (1C), while in children such mon itoring is suggested already in stage 2 due to the risk of growth disturbance and cardiac dys function (2D). Suggested frequency of monitoring various bio chemical para meters is presented in the TAbLE. Such frequency will depend on the clin ical picture, disease progression, potential distur bances in mineral homeostasis, and the type of treatment (monitoring treatment efficacy).
The authors of the guidelines suggest using in dividual values of calcium and phosphorus levels rather than the mathematical calculation of calcium phosphorus product (Ca × P), which is mostly re flecting the phosphorus level, and as such it has no major significance in the diagnostic process (2D). At the same time, they stress the importance of methodology and inter pretation of the results, stating that laboratories should inform clinicians about the applied measurement methods, as well as proper blood sampling and handling proto cols (1B), since any misinformation in that mat ter can lead to inconsistencies or distortion of the results. Decisions regarding introduction of therapeutic modalities should rely on serial mea surements of a given para meter rather than in dividual values (1C). For example, an increase in and released a preliminary report, which was then analyzed by the KDIGO Board. The final version was subsequently published on the Internet for public review. The guidelines were for the first time presented in public during the American So ciety of Nephrology congress in 2008, and sub sequently published in the August 2009 issue of Kidney International. 1 Moreover, while working on the guidelines, KDIGO developed a system of rating the strength of recommendations and the underlying quali ty of evidence. After long debates, the modified "Grading of Recommendations Assessment, De velopment, and Evaluation System" was finally approved by the KDIGO Board in 2008. The sys tem is an important key to inter pret the guide lines. The authors use 2 levels of recommenda tion: strong (level 1) -the guidelines should be treated as recommendations, and weak (level 2) -the guidelines should be treated as suggestions.
The quality of underlying evidence was graded as: A -high, B -moderate, C -low, and D -very low. Additional personal expert opinions were presented as "not graded". Overall, recommen dations of the CKDMBD guidelines are weak: only 10 of 58 recommendations reached level 1, and only 2 of these 10 recommendations were supported by highquality evidence (A). The lat ter included human recombinant growth hor mone therapy in children and youth, as well as the treatment of osteoporosis in patients with CKD stages 1-2 (see below). In the present re view, the numbers and letters in parentheses will indicate the level of recommendations and qual ity of evidence for particular guidelines in keep ing with the KDIGO classification.
The full document has 130 pages and contains the guidelines along with detailed commentaries, tables, and literature references. The chapters discuss the following: 1) definition of CKBMBD, 2) diagnosis of bio chemical abnormalities, various types of bone disorders, and vascular calcification, 3) treatment of calciumphosphorus disturbanc es and abnormal levels of para thormone (PTH), 4) treatment of bone disorders with bisphos phonates, other osteoporosis medications, and growth hormone, 5) evaluation and treatment at a constant rate of mineralization, an increase in BMD is usually observed. The KDIGO experts did not formulate any guidelines concerning bone bio psy, because it is rare in clinical practice, and there are not many anatomical patho logists with relevant experi ence. However, the experts state that bone bio psy may be justified in some cases in CKD stag es 3-5, including patients on dialysis (5D). These include unexplained bone fractures, unrelent ing bone pain, unexplained hypophosphatemia or hypercalcemia, rare cases of aluminum oste opathy; it may also be used prior to the adminis tration of bisphosphonates to exclude adynam ic bone disease, which is a contraindication for such therapy.
diagnosis of CKd-Mbd: soft tissue calcification
Multislice computed tomography, which allows to determine coronary calcification, is an expen sive method and is not neutral for the patient; therefore, it should be treated merely as a refer ence method. In a clinical setting, diagnosis of cardiovascular calcifications in CKD stages 3-5D should be thus based on a much more broadly available lateral abdominal radiograph to detect aortic calcifications (2C), and echocardiogram to detect valvular calcifications (2C).
Tests detecting cardiovascular calcifications in patients with CKD may become a part of routine screening in the future. However, the data are in sufficient to justify such an approach at present. While cardiovascular calcification is strongly pre dictive of cardiovascular events and death in pa tients with CKD, the introduction of anticalcifi cation therapies has not been shown to improve the longterm prognosis. An effective therapeu tic modality has not been established for such pa tients yet, and the role of calcimimetics or statins in their treatment remains elusive.
Nevertheless, a thorough diagnostic evalua tion of possible cardiovascular calcifications is justified in some circumstances, e.g., in patients with significant hyperphosphatemia who require a complex therapeutic inter vention, in prospec tive transplant recipients, and in patients whose therapy could be directly influenced by the de tection of calcifications (e.g., patients on hemo dialysis who would therefore become eligible for hemo diafiltration). The KDIGO experts sug gest that patients with calcification should be PTH levels observed in a series of measurements, rather than a single measurement, should indi cate a change of approach, even if the observed values are within the normal range.
diagnosis of CKd-Mbd: bone disease Diagnosis of bone disease is challenging, mainly because bone bio psy is still a rare test for various rea sons. Moreover, attempts to find a reliable and easily available bio chemical marker of bone dis ease have not been successful so far. Several pro posed markers, such as the products of collagen synthesis (procollagen type I Cterminal propep tide) and breakdown (Ctelopeptide type I colla gen, Ntelopeptide type I collagen, pyridinoline or deoxypyridinoline), did not prove better than the traditionally measured serum PTH; there fore, the recommendation for their routine use in clinical practice is weak (2C). Simultaneous measurement of serum PTH and alkaline phos phatase (ALP) levels has proved to be the most reliable tool to date. However, it should be noted that type of osteodystrophy can be predicted only when these levels are significantly elevated or de creased (2B). The diagnostic value of densitome try is also relatively low, because it does not allow for differentiating between various types of bone patho logies, and bone mineral density (BMD) is not a reliable predictor of bone fractures in CKD patients (2B). Nevertheless, children should be carefully monitored with respect to their linear growth: infants should be assessed at least quar terly (1B), children at least annually (1B).
Definitive diagnosis of renal osteodystrophy re lies on a comprehensive histomorphometric anal ysis. Until recently, such analysis has been based mainly on determining the rate of bone turn over and proper mineralization. During the 2005 Controversies Conference, where the guidelines discussed here were initiated, an introduction of the TMV (Turnover, Mineralization, Vol ume) classification to the diagnosis of renal os teodystrophy was proposed. It has been used by the American Society for Bone and Mineral Re search since 1987.
2 The classification introduces the third para meter that describes bone changes, namely the bone volume. It affects bone fragility and is a result of equilibrium that exists between bone formation and resorption rates: if such bal ance is positive, the bone volume increases, and, Abbreviations: ALP -alkaline phosphatase, Tx -kidney transplant, others -see FIGURE bone resistance to PTH in patients with progres sive renal disease. 3 However, it still remained un clear whether achieving the recommended lev els of PTH correlated with the normalization of bone meta bolism. This is complicated by the fact that mineral and bone abnormalities are inter related with the cardiovascular system. Impor tantly, what is favorable for the former may prove detrimental for the latter. Therefore, assuming that the optimal PTH level is currently unknown, the KDIGO workgroup suggests monitoring cal cium, phosphorus, and calcidiol levels in patients with CKD stages 3-5 with abnormal PTH levels (2C). An increase in PTH levels may be a possi ble adaptive process and can be reversed to nor mal values after normalizing other para meters of calciumphosphorus homeostasis. However, if increased serum levels of PTH are maintained, treatment with calcitriol or its analogs can be considered (2C). The KDIGO experts suggest a different ap proach in dialyzed patients: their PTH serum levels should be maintained within the range of approximately 2 to 9 times the upper normal limit (2C). It is one of the major changes intro duced by KDIGO, since the 2003 K/DOQI guide lines suggested a range of 3 to 6 times the upper normal limit. 3 Broadening the range of accept able PTH levels is supported by evidence. First, crosssectional studies have suggested that while CKD progresses, both the mean levels as well as the range values of PTH levels increase. As a re sult, the predictive value of PTH as a marker of bone disease within the 2 to 9 times normal limit is fairly low. Second, methodo logical difficulties concerning measurement of PTH cannot be ig nored. Various tests measure varying amounts of accumulating PTH fragments, including the an tagonistic fragment C 7-84 . As a result, high con centrations of intact PTH may coexist with a rel ative hypoparathyroidism at the bone level.
KDIGO suggestion to carefully monitor trends in serial PTH measurement deserves particular attention -any definite shifts towards the upper or lower limit should be a clear signal to modify the therapy in such a way as not to exceed the ac ceptable range (2C). On the other hand, a general trend towards one direction observed in the ma jority of tested patients in one center may sug gest a recent change in the methodology of PTH measurement in a given laboratory.
While reviewing the treatment of CKDMBD, the authors of the guidelines avoid any sugges tions concerning the choice of any particular med ication, mainly because there is not enough evi dence to support any specific selection. They only recommend the use of calcitriol or its analogs, cal cimimetics, or a combination of vitamin D an alogs and calcimimetic in the case of increased PTH levels. The choice of therapeutic modality should be based on the presence of possible con traindications in each individual case. For exam ple, hypercalcemia will be a clear contraindica tion for administering vitamin D analogs, and considered at the highest cardiovascular risk (2A), and therefore, any existing atherosclerosis risk factors should be eliminated, and a meticulous control of bio chemical para meters of calcium phosphorus homeostasis ensured. Although there is no evidence to support this, the experts consid er it reasonable to limit the use of calciumbased phosphate binders in such patients.
Treatment of CKd-Mbd: calcium-phosphorus homeostasis Phosphorus levels in patients in predial ysis stages of CKD should be maintained with in the normal range (2C). In dialyzed patients, such strict management protocol may be par ticularly difficult. Although we should certain ly aim at achieving normal phosphorus levels in this group, in some patients it may simply be im possible or may lead to lowering their quality of life, undernourishment (too restrictive diet), or side effects when too strong doses of intestinal phosphate binders are administered. Therefore, the KDIGO Workgroup allowed for certain flex ibility in this respect and identified their recom mendation as weak (2C).
Calcium levels in CKD stages 3-5D should be maintained within the normal range (2D). Howev er, the experts argued that there was no sufficient evidence to support the Kidney Disease Outcomes Quality Initiative (K/DOQI) recommendation to maintain calcium levels within the lower margins of the normal range (T.B. Drüeke, personal com munication). Suggested calcium dialysate level should not exceed 1.25-1.50 mmol/l (2D).
The clinical practice guidelines for patients with hyperphosphatemia have not changed for years. Lowphosphate diet is suggested, although the strength of recommendation is surprisingly weak (2D). Dialysis efficiency needs to be further increased, which is an easy and relatively inexpen sive process, although not supported by strong evidence (2C). Intestinal phosphate binders, al though used for years in the prevention of hy perparathyroidism and treatment of hyperphos phatemia, are only suggested as a possible regi men due to the lack of randomized studies (2B). The workgroup does not recommend any partic ular binding agent due to the lack of sufficient data. As a logical consequence, each treatment should be customized, i.e., adjusted individually to the patient's clinical para meters. For example, it is strongly recommended to lower the dose or even to completely withdraw calciumbased med ications and vitamin D analogs in patients with persistent or recurring hypercalcemia (1B). Low er doses of calciumbased preparations are also suggested in patients with significant vascular calcification or those who have persistently low PTH levels (2C).
Treatment of CKd-Mbd: abnormal PTH levels De termining the optimal serum PTH level re mains one of the weakest points of clinical prac tice. So far, it has been arbitrarily established at 150-300 pg/ml, based on a gradual increase in in CKD patients as compared with the general population. As reported by the National Health and Nutrition Survey, osteoporosis was diagnosed in 23% of adult women with CKD stages 3-4. 5 According to recent studies in the United States, 61% of women suffering from osteoporosis were in stage 3 and 23% in stage 4 of CKD. 5 Increased prevalence of osteoporosis signifi cantly increases the risk of bone fractures in pa tients with CKD. Nevertheless, unlike in the gen eral population, BMD value is not an accurate pre dictor of bone fractures in CKD due to a consid erable role of qualitative changes in the bone tis sue as well as the presence of other CKDrelated risk factors. Bone fractures occur in 10% to 40% of dialysis patients and in approximately 50% of patients older than 50 years. 1 The risk of hip frac ture in the population with endstage renal dis ease was reported to be up to 4fold higher than in the general reference population. 6 Evidence supporting the role of bisphospho nates in preventing bone fractures in patients with stage 3-5D of CKDMBD is not conclusive (C), because it is derived from post hoc analyses of large scale trials designed to study the treat ment of osteoporosis in the general population.
7,8
It is possible that some patients in stage 4-5D, es pecially those with low BMD and a high rate of bone turnover, after mineral disturbances and increased PTH levels are normalized, may bene fit from bisphosphonate therapy, but only large, wellplanned, randomized trials can provide a reli able answer to this question. Moreover, the guide lines emphasize the need for further studies that would investigate the pharmacodynamics of bis phosphonates in patients with CKD.
Of note, bisphosphonates have an antiresorp tive potential; they can be incorporated into the bone tissue and remain there for several years (T 1/2 >10 years), which severely and almost per manently slows down the rate of bone turnover. Other serious side effects include mandibular os teonecrosis, arrhythmia, ulcerations of the upper part of the gastrointestinal tract, and nephritic syndrome. Therefore, the decision to administer bisphosphonates has to be supported by clinical data. Since the risk of inducing adynamic bone disease significantly increases with the progres sion of CKD, administering bisphophonates in pa tients in stages 4-5D (especially in those already on dialysis) should be preceded by bone bio psy in order to exclude the possibility of a decrease in bone turnover rate (2D).
According to the authors of the guidelines, there is not enough data concerning other an tiosteoporotic medications (e.g., recombinant active PTH 1-34 , teriparatide, or a selective estro gen receptor modulator -raloxifene) to allow for any recommendations or even suggestions to be formulated.
In children with CKD stages 2-5D and associ ated height deficits, the treatment with human recombinant growth hormone is recommend ed, providing that the coexistent malnutrition the treatment will either have to be stopped or reduced (1B); similar although much weaker rec ommendation was formulated for hyperphos phatemia (2D). Similarly, hypocalcemia is a clear contraindication for calcimimetics, and withdraw al or dose reduction is recommended depending on disease severity, symptoms, and the use of oth er medications (2D). In severe secondary hyper parathyroidism, which is resistant to pharmaco logical inter vention, para thyroidectomy should be considered, although there is no reliable evidence for its effect on any of the hard endpoints.
In the case of 25(OH)D 3 deficiency, it should be supplemented in accordance with the guidelines concerning the general population (2C).
Treatment of CKd-Mbd: bisphosphonates and other medications Diagnosis of osteoporosis with the use of densitometry is feasible only in stages 1 and 2 of CKD (1A), and the diagnostic process and therapeutic approaches para llel the guidelines for the general population. Low BMD is the main di agnostic feature of osteoporosis. Since defective bone quality with normal or even increased min eral para meters is a typical feature of CKDMBD, the assessment of structural imperfections is even more complex and dependent on histomorpho metric analysis.
In stage 3 of the disease diagnosing osteoporo sis is possible, although much less reliable (2B), be cause stage 3 encompasses a very heterogeneous group of cases, as clearly reflected by a broad range of glomerular filtration rate (GFR) values charac teristic for this group (30-60 ml/min/1.73 m 2 ). There are limited data on the pathomorpho logical changes within the bone tissue at this stage of disease. The rare reports indicate high degree of heterogeneity in terms of both abnormal bone histology and the rate of bone turnover.
4 There fore, stage 3 of CKD requires introduction of in dividualized treatment.
The authors of the guidelines suggest that pa tients with low BMD and asymptomatic course of the disease, especially those with higher GFR values, can be managed using the guidelines for the treatment of osteoporosis in the general pop ulation. However, prior to establishing the diag nosis of osteoporosis, secondary hyperparathy roidism must be excluded and serum PTH mea sured. If PTH levels are normal, then, similarly to stages 1 and 2, stage 3 patients can be treated according to the general guidelines (2B). Never theless, the occurrence of CKD symptoms will re quire a change of therapeutic protocol and its ad justment according to the degree of disturbanc es, their possible reversibility, and progression of the disease. If GFR remains stable and the risk of bone fractures is higher than the risk associated with induced adynamic bone disease, administer ing bisphosphonates, preferably after bone bio psy, becomes a viable option (2D).
Later stages of CKD with low BMD are charac terized as CKDMBD with low BMD. Percentage of individuals with low BMD is significantly higher for innovative approaches or specific numbers. However, the guidelines are definitely a source of thorough and reliable analyses and commen taries, which are extremely instructive. They in dicate doubts and avoid categorical statements, and as such they teach us caution and a thought ful approach to clinical problems in question.
On the other hand, what may be disappoint ing is that the guidelines question even some of the most basic concepts (such as introducing low phosphorus diet or treatment with intestinal phosphorus binders) due to lack of evidence from randomized studies that will never be conducted. It only seems fair to ask whether our willingness to support the principles of evidencebased med icine did not lead us all slightly astray.
